For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…
Kaposi's sarcoma (KS) is a type of cancer that can form masses in the skin, lymph nodes, or other organs. The skin lesions are usually purplein color. They can occur singularly, in a limited area, or be widespread. It may worsen either gradually or quickly. Lesions may be flat or raised.
LPI (LP Information)' newest research report, the "Kaposi Sarcoma Industry Forecast" looks at past sales and reviews total world Kaposi Sarcoma sales in 2022, providing a comprehensive analysis by region and market sector of projected Kaposi Sarcoma sales for 2023 through 2029. With Kaposi Sarcoma sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Kaposi Sarcoma industry.
This Insight Report provides a comprehensive analysis of the global Kaposi Sarcoma landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Kaposi Sarcoma portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Kaposi Sarcoma market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Kaposi Sarcoma and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Kaposi Sarcoma.
The global Kaposi Sarcoma market size is projected to grow from US$ 101.5 million in 2022 to US$ 124.1 million in 2029; it is expected to grow at a CAGR of 2.9% from 2023 to 2029.
Four sub-types are described: classic, endemic, immunosuppresion therapy-related, and epidemic. Classic KS tends to affect older men, be slow growing, and affect the legs. Endemic KS occurs in young adult males in Africa and can be more aggressive. Immunosuppresion therapy-related KS generally occurs in people following organ transplantation and mostly affects the skin. Epidemic KS occurs in people with AIDS and many parts of the body can be affected. The diagnosis is by tissue biopsy while the extent of disease may be determined by medical imaging.
This report presents a comprehensive overview, market shares, and growth opportunities of Kaposi Sarcoma market by product type, application, key players and key regions and countries.
Market Segmentation:
Segmentation by type
- Classic
- Endemic
- Immunosuppresion Therapy-Related
- Epidemic
Segmentation by application
- Hospital
- Cancer Research Institution
- Clinics
This report also splits the market by region:
- Americas
- - United States
- - Canada
- - Mexico
- - Brazil
- APAC
- - China
- - Japan
- - Korea
- - Southeast Asia
- - India
- - Australia
- Europe
- - Germany
- - France
- - UK
- - Italy
- - Russia
- Middle East & Africa
- - Egypt
- - South Africa
- - Israel
- - Turkey
- - GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
- Aphios
- Bristol Myers Squibb
- Cytori Therapeutics
- CytRx
- Eli Lilly and Company
- GlaxoSmithKline
- Roche
- Johnson and Johnson
- Merck
- Pfizer